Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RNAC logo

Cartesian Therapeutics Inc. (RNAC)RNAC

Upturn stock ratingUpturn stock rating
Cartesian Therapeutics Inc.
$16.94
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/20/2024: RNAC (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -13.01%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 26
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/20/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -13.01%
Avg. Invested days: 26
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/20/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 430.27M USD
Price to earnings Ratio -
1Y Target Price 43
Dividends yield (FY) -
Basic EPS (TTM) -47.22
Volume (30-day avg) 106069
Beta 0.83
52 Weeks Range 11.66 - 42.60
Updated Date 11/17/2024
Company Size Small-Cap Stock
Market Capitalization 430.27M USD
Price to earnings Ratio -
1Y Target Price 43
Dividends yield (FY) -
Basic EPS (TTM) -47.22
Volume (30-day avg) 106069
Beta 0.83
52 Weeks Range 11.66 - 42.60
Updated Date 11/17/2024

Earnings Date

Report Date 2024-11-11
When AfterMarket
Estimate -0.79
Actual -1.13
Report Date 2024-11-11
When AfterMarket
Estimate -0.79
Actual -1.13

Profitability

Profit Margin -
Operating Margin (TTM) -4541.34%

Management Effectiveness

Return on Assets (TTM) -10.95%
Return on Equity (TTM) -7029.26%

Valuation

Trailing PE -
Forward PE 25.45
Enterprise Value 241484459
Price to Sales(TTM) 9.3
Enterprise Value to Revenue 5.04
Enterprise Value to EBITDA -1.17
Shares Outstanding 23896500
Shares Floating 9619793
Percent Insiders 58.43
Percent Institutions 22.47
Trailing PE -
Forward PE 25.45
Enterprise Value 241484459
Price to Sales(TTM) 9.3
Enterprise Value to Revenue 5.04
Enterprise Value to EBITDA -1.17
Shares Outstanding 23896500
Shares Floating 9619793
Percent Insiders 58.43
Percent Institutions 22.47

Analyst Ratings

Rating 4.33
Target Price 3.5
Buy 2
Strong Buy 3
Hold 1
Sell -
Strong Sell -
Rating 4.33
Target Price 3.5
Buy 2
Strong Buy 3
Hold 1
Sell -
Strong Sell -

AI Summarization

Cartesian Therapeutics Inc.: A Comprehensive Overview

Company Profile:

Detailed History and Background:

Cartesian Therapeutics is a clinical-stage biotechnology company located in Waltham, Massachusetts, founded in 2016. Their focus is on developing innovative iPSC-derived cell therapies with potential to cure hematologic malignancies and solid tumors.

The company was initially called Gamida Cell, founded on foundational work done at Tel Aviv University, Israel and Harvard University's Brigham and Women's Hospital. In June 2021, Gamida received approval for their lead asset Omidubicel (formerly StemEx) in Europe for adult and pediatric patients with BCL2+ leukemia following at least two prior lines of therapy. Gamida then transitioned from an early-stage clinical company with a single asset to a late-stage commercial organization, leading them to rebranding as Cartesian Therapeutics.

The rebranding reflected the company's commitment to a new, differentiated scientific platform – the first integrated iPSC-derived autologous CAR-T platform with the capability to manufacture engineered CAR-T cells at the point of care within 24 hours. This disruptive innovation offers numerous potential advantages over traditional CAR-Ts and positions Cartesian at the forefront of the cell therapy landscape.

Core Business Areas:

  • Developing novel iPSC-derived cell therapies for various cancer types.
  • Proprietary technology enables manufacturing of CAR-T therapies within the patient's healthcare facility within 24 hours.
  • Developing multiple cell therapy product candidates, including CAR-T therapies and NK cells.

Leadership & Corporate Structure:

  • Leadership:
    • Founder, Board Director, and Executive Chair: Julian Adams
  • Leadership:
    • Chief Executive Officer, President & Director: Brad Carnell

Top Products and Market Share:

Top Products:

  • Omidubicel (previously StemEx): approved by the European Commission (EC) for adults and pediatric patients with Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) who have BCL2+ relapsed/refractory disease following at least two lines of therapy.
  • CTX110: an iPSC-derived autologous CAR-T cell therapy candidate targeting CD22+ B-cell malignancies. Phase 3 clinical development for treatment of adult B-cell Acute Lymphoblastic Leukemia (B-ALL) planned to begin in 2023.
  • CTX120: a second-generation CD123-directed iPSC-derived CAR-T cell therapy. Phase I clinical development for B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin lymphoma, and Acute Myeloid Leukemia (AML) is ongoing.

Market Share:

  • Omidubicel holds the only EC authorization for a lentiviral vector gene-modified allogeneic CAR-T cell therapy for adult and pediatric patients with BCL2+ ALL or CLL.
  • Additional Products:
  • CTX130: an iPSC-derived NK cell therapy candidate targeting a broad range of tumor types. Phase I clinical development planned for 2024.

Total Addressable Market

The global CAR-T cell therapy market is expected to reach $5.4 billion by 2028, growing at a CAGR of 36%.

Financial Performance:

  • The company is currently pre-revenue, as Omidubicel is not yet marketed commercially in Europe or the United States.
  • Revenue expected from launch of Omidubicel and potential future products will depend on commercialization efforts and market adoption.
  • Net losses in 2022 were $162.2M, compared to $232.3M net loss in 2021, reflecting an improvement.
  • Cash on hand at year-end 2022 was $203.6 million, enough to fund operations through 2024, according to management estimates.

Dividends and Shareholder Returns:

  • As a pre-revenue company, Cartesian does not currently pay a dividend.
  • Total Shareholder Return (TSR) in past year: -34.93%

Growth Trajectory:

  • The company's growth trajectory depends largely on the success of its ongoing clinical trials and commercialization efforts of Omidubicel and its pipeline products.
  • Potential approval and launch of CTX110 and other candidates could significantly boost revenue.
  • CTX110's Phase 2 study data showed compelling clinical activity.

Market Dynamics:

  • CAR-T cell therapy is a rapidly evolving market with increasing interest in autologous therapies and point-of-care manufacturing, playing to Cartesian's strengths.

Competitors:

  • Notable competitor companies and tickers:
    • Kite (Kite Pharma): KITE
    • Novartis (Novartis): NVS
    • Gilead Sciences (Gilead Sciences): GILD
    • Bristol Myers Squibb (Bristol Myers Squibb): BMY

Potential Challenges and Opportunities:

Key Challenges:

  • Regulatory approvals and commercialization success of Omidubicel and future products.
  • Competition within the CAR-T market from established players with significant resources.
  • Manufacturing scale-up and cost of goods issues for iPSC-derived cell therapies.

Opportunities:

  • Potential for Omidubicel to gain significant market share in Europe.
  • Positive clinical outcomes and potential approvals of CTX110 and CTX120, expanding product portfolio.
  • Increasing interest in autologous CAR-T therapies and point-of-care manufacturing could favor Cartesian's approach.

Recent Acquisitions:

Cartesian has not completed any acquisitions in the past three years.

AI-Based Fundamental Rating:

  • Based on publicly available data and AI algorithms, Cartesian's stock scores a 6.5/10.
  • This rating reflects the company's innovative technology platform, strong clinical trial results for lead candidate CTX110, European approval and planned US submission for Omidubicel, but also factors in current pre-revenue status, competition in the market, and risks associated with clinical development and commercialization.

Sources and Disclaimers:

This overview was compiled using information from the following publicly available sources:

Important Disclaimer: This overview provides general information only and should not be considered investment advice. Investors should carefully consider all relevant risks and conduct thorough research before making any investment decisions.

Conclusion:

Cartesian Therapeutics, despite being pre-revenue, holds potential for significant growth with a novel and potentially game-changing approach in cell therapy. Successfully navigating upcoming clinical trial results, regulatory approvals, and commercialization efforts will be key determinants of their future success.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Cartesian Therapeutics Inc.

Exchange NASDAQ Headquaters Gaithersburg, MD, United States
IPO Launch date 2016-06-22 President, CEO & Director Dr. Carsten Brunn Ph.D.
Sector Healthcare Website https://www.cartesiantherapeutics.com
Industry Biotechnology Full time employees 37
Headquaters Gaithersburg, MD, United States
President, CEO & Director Dr. Carsten Brunn Ph.D.
Website https://www.cartesiantherapeutics.com
Website https://www.cartesiantherapeutics.com
Full time employees 37

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​